Roberts Capital Advisors LLC Acquires Shares of 6,109 Johnson & Johnson $JNJ

Roberts Capital Advisors LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 6,109 shares of the company’s stock, valued at approximately $1,133,000. Johnson & Johnson comprises about 1.3% of Roberts Capital Advisors LLC’s portfolio, making the stock its 19th biggest holding.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Johnson & Johnson by 9.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 189,990 shares of the company’s stock worth $35,228,000 after buying an additional 16,054 shares during the last quarter. Basepoint Wealth LLC bought a new stake in Johnson & Johnson during the third quarter worth $247,000. Tennessee Valley Asset Management Partners purchased a new position in Johnson & Johnson in the third quarter worth $577,000. SageView Advisory Group LLC boosted its position in Johnson & Johnson by 38.9% in the third quarter. SageView Advisory Group LLC now owns 30,164 shares of the company’s stock worth $5,593,000 after purchasing an additional 8,453 shares during the last quarter. Finally, Kepler Cheuvreux Suisse SA bought a new position in Johnson & Johnson in the 3rd quarter valued at $15,448,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approval of TECVAYLI (teclistamab) plus DARZALEX FASPRO for relapsed/refractory multiple myeloma broadens J&J’s oncology offering and could accelerate uptake in earlier lines of therapy, supporting revenue growth expectations. Johnson & Johnson (JNJ) Announces the FDA Approval of TECVAYLI® plus DARZALEX FASPRO®
• Positive Sentiment: EU approval to expand Akeega’s use in BRCA‑mutated metastatic hormone‑sensitive prostate cancer increases the drug’s addressable market in Europe and should support oncology franchise sales. JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
• Positive Sentiment: JNJ filed with the EMA to expand TECVAYLI monotherapy into earlier-line relapsed/refractory multiple myeloma after MajesTEC‑9 phase III data showing survival gains — a regulatory pathway that could materially extend TECVAYLI’s market. JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
• Positive Sentiment: Citigroup raised its price target to $274 and kept a Buy rating, implying notable upside vs. current levels — analyst support that can help lift investor sentiment. Benzinga
• Neutral Sentiment: JNJ presented at Barclays’ Global Healthcare Conference (transcript available) — useful for management commentary on growth drivers but unlikely to move the stock by itself. Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Coverage pieces (valuation review, inclusion on a “safest dividend aristocrats” list) are drawing renewed investor attention but don’t directly change fundamentals. Assessing Johnson & Johnson (JNJ) Valuation
• Negative Sentiment: Short interest rose ~20.8% in late‑Feb to ~25.1M shares, increasing potential downside pressure if bearish sentiment persists or if volatility triggers additional selling. Article: Short interest report
• Negative Sentiment: Two J&J units agreed to pay $65M to settle a Tracleer antitrust class action — a modest hit to cash and an added legal overhang, though not material to enterprise value. Johnson & Johnson (JNJ) Units to Pay $65 Million in Tracleer Antitrust Class Action Settlement, Reuters Reports

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares in the company, valued at $6,540,469.77. This represents a 45.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Down 0.3%

Shares of JNJ stock opened at $243.06 on Thursday. The stock has a market capitalization of $585.75 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 2.41 and a beta of 0.34. The company’s fifty day simple moving average is $230.52 and its two-hundred day simple moving average is $205.54. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The company had revenue of $24.28 billion during the quarter. As a group, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on JNJ shares. Rothschild & Co Redburn lifted their target price on Johnson & Johnson from $180.00 to $210.00 and gave the stock a “neutral” rating in a research note on Thursday, February 19th. Barclays raised their price objective on shares of Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 30th. Guggenheim boosted their target price on shares of Johnson & Johnson from $227.00 to $240.00 and gave the company a “buy” rating in a research note on Friday, January 23rd. Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $250.00 price target on shares of Johnson & Johnson in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $235.91.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.